Background
Methods
Tissue specimens
Immunofluorescence analysis
Scoring immunohistochemistry
Statistical analysis
Results
Patient and tumour characteristics
Parameter | N | Mean (95% CI)/Percentage of cases (%) |
---|---|---|
Age
| 148 | 56.6 years (54.5-58.6) |
Tumour size
| 149 | 26.6 mm (23.8-29.3) |
Tumour grade
| 149 | |
1 | 2 | 1 |
2 | 56 | 38 |
3 | 91 | 61 |
Lymph node involvement
| 145 | |
Yes | 69 | 48 |
No | 76 | 52 |
ER status
| 149 | |
Positive | 87 | 58 |
Negative | 62 | 42 |
PR status
| 149 | |
Positive | 79 | 53 |
Negative | 70 | 47 |
Her2 status
| 149 | |
Positive | 12 | 8 |
Negative | 137 | 92 |
Molecular sub-type
| 149 | |
Luminal A | 56 | 38 |
Luminal B | 31 | 21 |
Her2 positive | 12 | 8 |
TN | 50 | 33 |
Correlation between endothelial and tumour cell FAK expression
Tumour endothelial-FAK expression and relation with clinicopathological factors
FAK location | Parameter | Correlation co-efficient | p-value |
---|---|---|---|
Vessels | Patient age | 0.096 | 0.246 |
Tumour size | 0.089 | 0.28 | |
Tumour cells | Patient age | -0.138 | 0.094 |
Tumour size | 0.119 | 0.148 |
FAK location | Parameter | Mean FAK score (95% CI) | p-value |
---|---|---|---|
Vessels
|
Tumour grade
| ||
1 or 2
|
156.2 (124.6-187.8)
| ||
3
|
200.2 (177.9-222.6)
|
0.008
| |
Lymph node involvement
| |||
Yes | 184.7 (157.7-211.7) | ||
No | 179.6 (152.8-206.5) | 0.765 | |
ER status
| |||
Positive
|
161.3 (139.9-184.6)
| ||
Negative
|
213.7 (184.7-242.7)
|
0.005
| |
PR status
| |||
Positive
|
156.8 (131.6-181.9)
| ||
Negative
|
212.8 (186.7-238.9)
|
0.002
| |
Her2 status
| |||
Positive
|
215.8 (181.6-250.0)
| ||
Negative
|
169.8 (148.0-191.6)
|
0.022
| |
Molecular sub-type
| |||
Luminal A vs Non-Luminal A
|
135.4 (107.6-163.2) vs 211.8 (189.0-234.6)
|
<0.001
| |
Luminal B vs Non-Luminal B | 208.0 (169.1-246.9) vs 176.5 (155.5-196.6) | 0.130 | |
Her2 positive vs Non-Her2 | 235.9 (155.8-316) vs 178.5 (159.5-197.4) | 0.121 | |
TN versus Non-TN
|
208.4 (176.6-240.1) vs 170.3 (147.6-193.0)
|
0.043
| |
Tumour cells
|
Tumour grade
| ||
1 or 2
|
4.1 (3.6-4.7)
| ||
3
|
5.1 (4.8-5.5)
|
0.001
| |
Lymph node involvement
| |||
Yes | 5.1 (4.7-5.4) | ||
No | 4.5 (4.0-5.0) | 0.249 | |
ER status
| |||
Positive
|
4.4 (4.0-4.9)
| ||
Negative
|
5.2 (4.8-5.6)
|
0.013
| |
PR status
| |||
Positive
|
4.4 (4.0-4.9)
| ||
Negative
|
5.1 (4.7-5.5)
|
0.048
| |
Her2 status
| |||
Positive | 5.1 (4.6-5.6) | ||
Negative | 4.6 (4.2-5.0) | 0.215 | |
Molecular sub-type
| |||
Luminal A vs Non-Luminal A
|
4.1 (3.5-4.7) vs 5.2 (4.8-5.5)
|
0.001
| |
Luminal B vs Non-Luminal B | 5.0 (4.4-5.6) vs 4.7 (4.3-5.0) | 0.408 | |
Her2 positive vs Non-Her2 | 5.3 (4.5-6.1) vs 4.7 (4.4-5.0) | 0.406 | |
TN versus Non-TN
|
5.2 (4.7-5.7) vs 4.5 (4.1-4.9)
|
0.033
|
FAK expression in tumour cells in relation to clinicopathological factors
Correlation of FAK expression and established prognostic factors with the Luminal A sub-type – univariate regression
Parameter | LR Chi Square | OR (95% CI) | p-value |
---|---|---|---|
Age at diagnosis | 11.12 | 1.01 (0.99-1.04) | 0.413 |
Tumour size | 0.05 | 1.00 (0.98-1.02) | 0.823 |
Tumour grade
|
32.03
|
0.13 (0.06-0.27)
|
<0.001
|
Lymph node status | 2.06 | 0.61 (0.31-1.20) | 0.154 |
FAK tumour cells
|
11.41
|
0.11 (0.03-0.42)
|
0.001
|
FAK vessels
|
17.11
|
0.02 (0.01-014)
|
<0.001
|
Independent correlation of endothelial-FAK with the Luminal A sub-type
Parameter | Stepwise entry | LR Chi Square | OR (95% CI) | p-value |
---|---|---|---|---|
Tumour Grade | 1 | 32.03 | 0.14 (0.07-0.31) | <0.001 |
FAK vessels | 2 | 11.31 | 0.03 (0.01-0.25) | 0.001 |